Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Skin Neoplasms 2Lymphoma 2Lymphoma, T-Cell 1

Interventions

zanolimumab 2cemiplimab 1cc-486 1Sirolimus 1SUB1 protein, human 1Quality of Life 1Psychiatric Rehabilitation 1Prednisone 1Patient Reported Outcome Measures 1Observation 1Molecular Diagnostic Techniques 1Mass Screening 1Injections 1Immunotherapy 1Hematologic Tests 1Everolimus 1Drug Therapy 1Dasatinib 1Biological Therapy 1Azacitidine 14,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Skin Neoplasms × zanolimumab × Lymphoid × Clear all
NCT00071071 2023-05-18

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
25 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00071084 2023-04-28

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
22 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡